LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN Jan 29, 2023 06:30PM
MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY Jan 26, 2023 06:30PM
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023 Jan 18, 2023 08:08AM
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN Jan 15, 2023 07:30PM
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE Jan 10, 2023 06:30PM
View Older Stories

Jan 6, 2023 11:30PM Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jan 6, 2023 02:31PM Eisai, Biogen (BIIB) Confirm FDA Approval of LEQEMBI Under Accelerated Approval Pathway for Treatment of Alzheimer's Disease
Jan 6, 2023 02:30PM FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
Dec 22, 2022 06:45PM EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA
Dec 22, 2022 03:07AM Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Dec 21, 2022 08:00PM Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Dec 1, 2022 08:08AM Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
Nov 29, 2022 08:33PM Eisai, Biogen Phase 3 Results of Lecanemab in Early Alzheimer's Show Highly Statistically Significant Results
Nov 29, 2022 07:50PM ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND
Nov 29, 2022 07:50PM EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
Nov 23, 2022 06:30PM EISAI TO PRESENT LATEST DATA ON FYCOMPA® (PERAMPANEL) CIII AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING
Oct 21, 2022 10:30AM Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
Sep 28, 2022 07:00AM Eisai, Biogen (BIIB) Announce Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint for Reduction of Early Alzheimer's Disease
Sep 27, 2022 07:30PM LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH E
Sep 10, 2022 05:20AM Eisai Presents Results of Post-Hoc Analysis of Eribulin Mesylate (HALAVEN®) at the European Society for Medical Oncology (ESMO) Congress 2022
Sep 6, 2022 08:08AM Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
Aug 23, 2022 09:00AM C2N and Eisai Collaborate to Build Awareness and Real-World Evidence for Blood-Based Assays for Cognitive Impairment in Clinical Practice Outside of Clinical Trial Settings
Aug 18, 2022 10:05AM Eisai Inc. Reinforces Commitment to Collaboration and Innovation to Support Patients and Communities Through New U.S. Headquarters
Aug 4, 2022 08:08AM BASEBALL LEGEND BERNIE WILLIAMS TEAMS UP WITH EISAI AND ADVOCACY PARTNERS TO LAUNCH ONE LIVER TO LOVE INITIATIVE TO HELP RAISE AWARENESS ABOUT LIVER CANCER AND THE IMPORTANCE OF LIVER HEALTH
Aug 3, 2022 07:32PM EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENC
Jul 27, 2022 08:00AM Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
Jul 5, 2022 07:30PM THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Jun 5, 2022 09:00AM Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
Jun 2, 2022 07:30PM EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING
May 27, 2022 08:08AM Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
May 9, 2022 07:31PM EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Apr 4, 2022 10:01AM Geisinger, Eisai team up to study use of artificial intelligence for early detection and identification of cognitive impairment that could indicate dementias, including Alzheimer's disease
Mar 31, 2022 08:00AM EISAI TO PRESENT DATA ON NEUROLOGY PORTFOLIO IN THE AREAS OF ALZHEIMER'S DISEASE, SLEEP AND EPILEPSY AT THE 74th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING
Mar 30, 2022 07:57AM MEAGAN GOOD SHARES HER SCARE WITH UTERINE CANCER TO ENCOURAGE PEOPLE TO SPOT THE EARLY SIGNS OF ENDOMETRIAL CANCER AS PART OF EISAI AND ADVOCACY PARTNERS' SPOT HER® CAMPAIGN
Mar 21, 2022 07:30PM LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING
Mar 10, 2022 06:30PM Eisai To Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State Symposium, and Other Pipeline Assets at the AD/PD™ 2022 Annual Meeting
Mar 3, 2022 06:30PM EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBO
Jan 24, 2022 08:05AM EISAI INC. ANNOUNCES THE APPOINTMENT OF TRICIA BROOKS AS VICE PRESIDENT & HEAD OF OFFICE, GOVERNMENT AFFAIRS AND POLICY
Jan 14, 2022 08:08AM Eisai to Present Research at the 2022 ASCO Gastrointestinal Cancers Symposium in Multiple Tumor Types from its Robust Oncology Portfolio
Dec 23, 2021 06:30PM INVESTIGATIONAL ALZHEIMER'S DISEASE THERAPY LECANEMAB GRANTED FDA FAST TRACK DESIGNATION
Dec 7, 2021 11:36AM Eisai Presents Its Largest Real-World Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) Across Patient Types At The 2021 American Epilepsy Society (AES) Annual Meeting
Dec 7, 2021 08:35AM #ThisIsMBC "fearLESS" Campaign Portrays Powerful Portraits of People Living fearLESSly with Metastatic Breast Cancer Through Friendship, Community and Making Each Day Count
Dec 7, 2021 08:00AM Eisai Presents Final Results Of Phase IV Elevate Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) At The American Epilepsy Society (AES) 2021 Annual Meeting
Dec 1, 2021 03:15PM Eisai To Present Real-World Evidence And Convulsive Seizure Freedom Data Evaluating FYCOMPA® (perampanel) Across Patient Types At 75th American Epilepsy Society (AES) Annual Meeting
Nov 28, 2021 07:15PM European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Nov 11, 2021 12:00PM Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening To Facilitate Identification Of Subjects For Phase 3 Ahead 3-45 Trial Presented At Clinical Trials On Alzheimer's Disease (CTAD) Confer
Nov 11, 2021 11:20AM Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference
Nov 10, 2021 02:57PM Eisai Presents Late-Breaker Updates On Lecanemab Clinical, Biomarker And Safety Data From Phase 2b Study Core And Open-Label Extension Across Five Years At Clinical Trials On Alzheimer's Disease (CTAD
Nov 4, 2021 08:10AM Eisai Presents New Data on the Relationship between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2b Study for Early Alzheimer's disease in Late-Breakers and Pipeline Updates at the
Oct 31, 2021 07:41PM The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)
Oct 17, 2021 07:00PM Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Two Different Types of Cancer
Sep 27, 2021 07:30PM Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway
Sep 27, 2021 12:50AM Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
Sep 13, 2021 08:08AM Data at ESMO Congress 2021 Underscore Depth of Eisai's Oncology Pipeline and Commitment to Cancer Care
Aug 30, 2021 07:42PM Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in Five ASEAN Countries
View Older Stories